Back to resultsClinical Trial for Prostate Cancer
Primary Purpose
Prostate Cancer
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Leuprolide Acetate for Injectable Suspension 22.5 mg
Sponsored by
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate, Cancer, PSA, Leuprolide
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00076531
First Posted
January 26, 2004
Last Updated
January 24, 2008
Sponsor
Oakwood Laboratories, LLC
1. Study Identification
Unique Protocol Identification Number
NCT00076531
Brief Title
Clinical Trial for Prostate Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
January 2008
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
November 2004 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Oakwood Laboratories, LLC
4. Oversight
5. Study Description
Brief Summary
Phase III trial using an injectable for treatment of prostate cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Prostate, Cancer, PSA, Leuprolide
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Masking
None (Open Label)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Leuprolide Acetate for Injectable Suspension 22.5 mg
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James A. Page, M.D.
Organizational Affiliation
Oakwood Laboratories, LLC
Official's Role
Study Chair
12. IPD Sharing Statement
Links:
URL
http://www.oakwoodlabs.com
Description
Oakwood (sponsor) site
Learn more about this trial
Clinical Trial for Prostate Cancer
We'll reach out to this number within 24 hrs